Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | SCN1A | P35498 | 3/20 | 0.43 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390423 | 0.84 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL562 | 0.84 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL8670912 | 0.83 | SLC6A3 (0.66) | SLC6A3SLC6A4SLC6A2LTB4R2BRS3 | |
| SCHEMBL5863187 | 0.82 | TSHR (0.57) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL28731490 | 0.81 | SCN1A (0.53) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL283 | 0.81 | SLC6A3 (0.48) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL9178840 | 0.81 | ALDH1A1 (0.56) | SLC6A3SCN1ASCN2ASCN3ASLC6A2 | |
| SCHEMBL29500197 | 0.81 | SCN1A (0.53) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL365731 | 0.80 | LTB4R2 (0.57) | CES2CES1LTB4R2BRS3 | |
| SCHEMBL29502712 | 0.80 | LTB4R2 (0.57) | CES2CES1LTB4R2BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150038725-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8889882-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-8541597-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120209008-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8188294-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188294-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038725-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | SLC6A3 383/4885SLC6A4 1495/4885SCN1A 4230/4885 |
| US-20110077411-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | SLC6A3 383/4885SLC6A4 1495/4885SCN1A 4230/4885 |
| US-20120209008-A1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | CYP4F3, CYP1B1, BMI1 | SLC6A3 383/4885SLC6A4 1495/4885SCN1A 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.